论文部分内容阅读
目的分析持续皮下注射给药技术治疗晚期癌症患者难治性癌痛的有效性。方法将100例晚期伴有难治性癌痛癌症患者按照治疗方法不同分为观察组54例和对照组46例。对照组给予常规吗啡制剂口服镇痛,观察组给予持续皮下注射吗啡。采用疼痛视觉模拟评分(VAS)对2组镇痛效果进行比较;采用生活质量评定表(SF-36)对2组患者治疗前后生活状态改善情况进行分析;并比较2组患者生存期。结果治疗后,2组患者VAS评分、SF-36评分较治疗前均有显著改善(P<0.05),但2组间VAS评分比较无明显差异(P>0.05)。观察组患者治疗后SF-36评分明显高于对照组,差异有统计学意义(P<0.05)。观察组患者预测生存期为(6.8±1.2)个月显著长于对照组的(4.7±1.1)个月,差异有统计学意义(P<0.05)。结论针对晚期癌症难治性癌痛患者来说,吗啡能在一定程度上缓解疼痛,针对不能口服吗啡的患者可行持续皮下注射给药,镇痛效果较好,且患者耐受性好,延长患者生存期。
Objective To analyze the effectiveness of continuous subcutaneous injection in the treatment of refractory cancer pain in patients with advanced cancer. Methods One hundred patients with advanced cancer with refractory cancer were divided into observation group (54 cases) and control group (46 cases) according to different treatment methods. The control group was given oral morphine analgesia, and the observation group was given morphine subcutaneously. The pain visual analogue scale (VAS) was used to compare the analgesic effects of two groups. The quality of life questionnaire (SF-36) was used to analyze the improvement of living conditions in two groups before and after treatment. The survival of the two groups was also compared. Results After treatment, the VAS scores and SF-36 scores of two groups were significantly improved (P <0.05), but there was no significant difference between the two groups in VAS score (P> 0.05). The SF-36 score of the observation group was significantly higher than that of the control group after treatment (P <0.05). The predicted survival time in the observation group was (6.8 ± 1.2) months significantly longer than that in the control group (4.7 ± 1.1) months, the difference was statistically significant (P <0.05). Conclusions For patients with advanced cancer refractory cancer pain, morphine can relieve pain to some extent. For patients who can not take orally morphine, it is feasible to administer subcutaneously subcutaneously, with good analgesic effect and good patient tolerance. Patients with prolonged Survival.